<DOC>
	<DOCNO>NCT00446368</DOCNO>
	<brief_summary>Patients metastatic renal cell cancer enrol receive RAD001 determine whether use RAD001 result improvement time tumor progression .</brief_summary>
	<brief_title>Safety Study RAD001 Treat Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>Patients metastatic renal cell cancer enrol study eligibility criterion meet agree participate . The participant take RAD001 ( Everolimus ) 10mg mouth day . During first cycle , blood work do week ( 4 week ) . On cycle thereafter blood work day 7 21 . Once month , patient chest x-ray . Every 8 week patient CT scan chest , abdomen pelvis . If clinically indicate , additional test do .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients must predominantly clear cell renal cancer ( 75 % ) Patients must evidence metastatic disease . Metastatic disease progress require palliative treatment ( e.g. , radiation , surgery , etc ) , within 4 week enrollment . Patients may receive two prior regimen immunotherapy , chemotherapy molecular target agent renal cell carcinoma least 1 regimen consist tyrosine kinase inhibitor ( sorafenib sunitinib ) . Four week must elapse previous therapy . Patients must adequate physiologic reserve evidence lab value Effective birth control must practice male female patient Patients central nervous system metastasis exclude , except patient complete excision radiotherapy remain asymptomatic , steroids 21 day , evidence new disease show MRI Patients known HIV positive eligible , although test specifically participation protocol require . Patients recent history TIA ( within 6 month ) , require regular antianginal therapy claudication sufficient limit activity eligible . Patients previous history deep venous thrombosis pulmonary embolism eligible . Patients active autoimmune disease . Patients steroid therapy within past three week . Patients involve concurrent anticancer drug therapy . Any immunosuppressive drug experimental therapy . Female patient pregnant lactating . The patient unstable medical condition , uncontrolled diabetes mellitus hypertension ; active infection require systemic antibiotic , antiviral , antifungal ; clinical evidence cardiac pulmonary dysfunction include , limited : unstable CHF ; uncontrolled arrhythmia ; unstable coagulation disorder ; recent myocardial infarction ( within 6 month ) . The patient receive investigational agent ( ) within 4 week study entry . Patients evidence mucosal internal bleeding and/or platelet refractory ( i.e. , unable maintain platelet count &gt; 50,000 cells/mm3 ) . Patients unable maintain absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm3 . Any condition , include laboratory abnormality , opinion Investigator place patient unacceptable risk he/she participate study . Prior malignancy ( within last 3 year ) except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree least 3 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>metastatic kidney cancer</keyword>
	<keyword>metastatic renal cell cancer</keyword>
</DOC>